Based on first-in-human phase 1 data where they evaluated the drug in previously treated patients, EGFRm NSCLC cohort (n = 38) had ORR of 63.2%, DCR of 89.5% (n = 38), and EGFR-WT (n = 50) had 44.0% and 94.0%, respectively, demonstrating potential efficacy in both mutated and non-mutated pre-treated NSCLC tumors and in patients who have progressed on EGFR TKIs [78]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.